20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
April 2023 in “Clinical Chemistry and Laboratory Medicine” The document concludes that inflammation markers can be used in diabetes, vitamin D3 affects immune pathways, hyperthyroidism changes hormone levels, androgen levels help diagnose Adrenocortical Carcinoma, erectile dysfunction is linked to diabetes, hypogonadism is common in HIV-infected males, and hormones can be biomarkers for various conditions.
September 2023 in “Journal of Cosmetic Dermatology” Finasteride was more effective than hydroxychloroquine in treating frontal fibrosing alopecia.
January 2022 in “Clinical, Cosmetic and Investigational Dermatology” A mix of methotrexate, corticosteroids, and topical minoxidil effectively treated severe total body hair loss, but caused stretch marks and needs long-term monitoring.
52 citations
,
February 2003 in “Archives of dermatology” 9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.
January 2025 in “International Journal of Trichology” Combining DPCP with PRP doesn't improve hair regrowth in alopecia areata.
4 citations
,
January 2022 in “Dermatology Research and Practice” Methotrexate alone is as effective and safe as combining it with prednisolone for treating Lichen planopilaris.
1 citations
,
July 2024 in “JAAD Case Reports” Gabapentin may help relieve itchy scalp in lichen planopilaris patients.
1 citations
,
January 2023 in “International Journal of Molecular Sciences” Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
2 citations
,
October 2021 in “Journal of Cosmetic Dermatology” Finasteride is more effective and satisfactory than montelukast for treating moderate acne in women.
77 citations
,
November 2018 in “Cell” Lung immune cells can be trained to better fight infections after a virus.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
10 citations
,
January 2019 in “International Immunology” Immune cells help keep skin healthy and repair it, but imbalance can cause disease.
7 citations
,
June 2020 in “JAAD Case Reports” Artificial hair implants can still cause side effects despite improvements.
1 citations
,
December 2022 in “Frontiers in Immunology” Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.
August 2023 in “Dermatologic Surgery” Person-to-person hair transplants can work for patients on lifelong immunosuppression, with high hair growth success.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
14 citations
,
November 2016 in “Lupus” Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
9 citations
,
December 2015 in “Journal of Dermatological Case Reports” Narrowband UVB therapy significantly improved a child's rare skin condition.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
2 citations
,
October 2022 in “Skin appendage disorders” Activated and non-activated PRP are equally safe and effective for treating alopecia areata.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.